Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

Imagem de Miniatura
Arquivos
art_MAIA_Costutility_analysis_of_methylphenidate_treatment_for_children_and_2016.PDF (1009.72 KB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2016
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRASILEIRA PSIQUIATRIA
Autores
MAIA, Carlos R.
STELLA, Steffan F.
WAGNER, Flavia
PIANCA, Thiago G.
CRUZ, Luciane N.
ROHDE, Luis A.
POLANCZYK, Carisi A.
Citação
REVISTA BRASILEIRA DE PSIQUIATRIA, v.38, n.1, p.30-38, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To perform a cost-utility analysis on the treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate immediate-release (MPH-1R) in children and adolescents from Brazil. Method: A Markov model was constructed to compare MPH-1R vs. no treatment. A 24 -week naturalistic study was conducted to collect transition probabilities and utility data. Effectiveness was expressed as quality -adjusted life -years (QALY), and costs reported in 2014 international dollars (1$). The perspective was the Brazilian Unified Health System as payer, and the time horizon was 6 years. Results: Of 171 patients, 73 provided information at baseline, and 56 at week 24. Considering the MPH-1R monthly cost of 1$ 38, the incremental cost-effectiveness ratio (ICER) of treatment was 1$ 9,103/QALY for children and 1$ 11,883/QALY for adolescents. In two-way sensitivity analysis, considering one Gross National Product per capita (1$ 11,530) as willingness-to-pay,a cost of no-treatment lower than 1$ 45/month would render MPH-IR a cost-saving strategy. Discussion: MPH-1R treatment of children and adolescents is cost-effective for ADHD patients from the Brazilian public health system perspective. Both patients and the healthcare system might benefit from such a strategy.
Palavras-chave
Attention deficit hyperactivity disorder, cost-utility analysis, methylphenidate
URI
https://observatorio.fm.usp.br/handle/OPI/14370
Referências
  1. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  2. American Psychological Association, 2013, DIAGN STAT MAN MENT
  3. Gilmore A, 2001, PHARMACOEPIDEM DR S, V10, P85, DOI 10.1002/pds.564
  4. Doshi JA, 2012, J AM ACAD CHILD PSY, V51, P990, DOI 10.1016/j.jaac.2012.07.008
  5. Swanson JM, 2001, J AM ACAD CHILD PSY, V40, P168, DOI 10.1097/00004583-200102000-00011
  6. Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
  7. Chan E, 2002, ARCH PEDIAT ADOL MED, V156, P504
  8. Donnelly M, 2004, AUST NZ J PSYCHIAT, V38, P592, DOI 10.1080/j.1440-1614.2004.01422.x
  9. [Anonymous], 2003, CNS DRUGS
  10. [Anonymous], 2010, J PUBLIC HLTH, DOI 10.1007/S10389-010-0315-0
  11. Husereau D, 2013, PHARMACOECONOMICS, V31, P361, DOI 10.1007/s40273-013-0032-y
  12. Cruz L, 2013, J MENT HEALTH, V22, P111, DOI 10.3109/09638237.2012.759193
  13. Petrou S, 2003, HEALTH ECON, V12, P697, DOI 10.1002/hec.775
  14. Ferri C, 2004, SOC PSYCH PSYCH EPID, V39, P218, DOI 10.1007/s00127-004-0729-5
  15. BARKLEY RA, 1990, PEDIATRICS, V86, P184
  16. COSTELLO EJ, 1985, J ABNORM CHILD PSYCH, V13, P579, DOI 10.1007/BF00923143
  17. Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172
  18. Maia CR, 2015, REV BRAS PSIQUIATR, V37, P67, DOI 10.1590/1516-4446-2014-1378
  19. Vieira FS, 2009, REV ASSOC MED BRAS, V55, P672, DOI 10.1590/S0104-42302009000600011
  20. Kieling C, 2011, LANCET, V378, P1515, DOI 10.1016/S0140-6736(11)60827-1
  21. Flisher AJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000235
  22. Shimoda S, 2005, QUAL LIFE RES, V14, P1407, DOI 10.1007/s11136-004-6127-3
  23. Thiruchelvam D, 2001, J AM ACAD CHILD PSY, V40, P922, DOI 10.1097/00004583-200108000-00014
  24. Shreeram S, 2009, J AM ACAD CHILD PSY, V48, P35, DOI 10.1097/CHI.0b013e318190045c
  25. Shimoda S, 2008, J PEDIAT HEMATOL ONC, V30, P563, DOI 10.1097/MPH.0b013e31816e231c
  26. Jensen PS, 2005, AM J PSYCHIAT, V162, P1628, DOI 10.1176/appi.ajp.162.9.1628
  27. Lima AFBD, 2013, REV BRAS PSIQUIATR, V35, P186, DOI 10.1590/1516-4446-2012-0989
  28. Ravens-Sieberer U, 2006, PHARMACOECONOMICS, V24, P1199, DOI 10.2165/00019053-200624120-00005
  29. Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724
  30. Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021
  31. Fletcher J, 2009, J MENT HEALTH POLICY, V12, P119
  32. Braun S, 2013, CLIN THER, V35, P673, DOI 10.1016/j.clinthera.2013.03.017
  33. Charach A, 2011, 12EHC003EF AG HEALTH
  34. Hong JY, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-15
  35. Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54
  36. Huntley Z, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-223
  37. IBM Corp, 2012, REL 2012 IBM SPSS ST
  38. King S, 2006, HEALTH TECHNOL ASSES, V10, pxiii
  39. King S, 2006, Health Technol Assess, V10, piii
  40. Lange H, 2014, J ATTEN DISORD
  41. Lindner Leandro Mendonça, 2009, Rev Saude Publica, V43 Suppl 1, P62, DOI 10.1590/S0034-89102009000800010
  42. Maia CRM, 2011, 8 ANN M HTAI RIO DE, P145
  43. Narayan Sangeeta, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P625, DOI 10.1586/14737167.4.6.625
  44. Robb J. A., 2011, SCH MENTAL HLTH, V3, P169, DOI 10.1007/S12310-011-9057-6
  45. Taylor E, 2004, EUR CHILD ADOLESC S1, V13, P17, DOI 10.1007/s00787-004-1002-x
  46. Vianna C, 2009, DIRETRIZES METODOLOG
  47. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology (WHOCC), 2014, DDD DEF GEN CONS

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21